Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | USP5 | P45974 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593309 | 0.88 | L3MBTL3 (0.33) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL81624 | 0.82 | L3MBTL1 (0.39) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL1394992 | 0.81 | L3MBTL1 (0.41) | L3MBTL1L3MBTL3ALDH1A1HRH3 | |
| SCHEMBL3436969 | 0.79 | L3MBTL1 (0.46) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL3598906 | 0.79 | L3MBTL3 (0.34) | L3MBTL1L3MBTL3ALDH1A1HRH3KDM4E | |
| SCHEMBL23269640 | 0.77 | L3MBTL1 (0.44) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL81246 | 0.77 | L3MBTL3 (0.41) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL1645820 | 0.77 | PHGDH (0.43) | L3MBTL1L3MBTL3ALDH1A1HRH3KDM4E | |
| SCHEMBL22519024 | 0.77 | L3MBTL1 (0.41) | L3MBTL1L3MBTL3ALDH1A1PIM1HRH3 | |
| SCHEMBL736079 | 0.77 | L3MBTL3 (0.48) | L3MBTL1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-110099899-A | Oxazole derivatives useful as IRAK inhibitors and process for preparing the same | 里格尔药品股份有限公司 | 2019-08-06 | — | — | CN | claimed |
| JP-2012500783-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | claimed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | claimed |
| CN-101426792-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT GMBH & CO KG (DE) | 2009-05-06 | — | — | CN | claimed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | claimed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | claimed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | claimed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | claimed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | claimed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | claimed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | claimed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | claimed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | claimed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | claimed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | claimed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | claimed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | claimed |
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-110099899-A | Oxazole derivatives useful as IRAK inhibitors and process for preparing the same | 里格尔药品股份有限公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-2833865-A1 | TREATMENT OF PROLIFERATIVE DISEASES WITH PYRIMIDODIAZEPINONES | Cyclacel Limited (GB) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013144632-A1 | TREATMENT OF PROLIFERATIVE DISEASES WITH PYRIMIDODIAZEPINONES | CYCLACEL LIMITED (GB) | 2013-10-03 | — | — | WO | disclosed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101426792-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT GMBH & CO KG (DE) | 2009-05-06 | — | — | CN | disclosed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7091227-B2 | Benzothiazole derivatives | ABBOTT GMBH & CO. KG (DE) | 2006-08-15 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | L3MBTL1 2877/4885L3MBTL3 2197/4885ALDH1A1 3091/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | L3MBTL1 3217/4885L3MBTL3 3537/4885ALDH1A1 81/4885 |
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | L3MBTL1 1551/4885L3MBTL3 3080/4885ALDH1A1 712/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | L3MBTL1 1749/4885L3MBTL3 2360/4885ALDH1A1 4236/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | L3MBTL1 3386/4885L3MBTL3 3594/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.